GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Waverley Pharma Inc (TSXV:WAVE) » Definitions » Current Ratio

Waverley Pharma (TSXV:WAVE) Current Ratio : 0.20 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Waverley Pharma Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Waverley Pharma's current ratio for the quarter that ended in Dec. 2023 was 0.20.

Waverley Pharma has a current ratio of 0.20. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Waverley Pharma has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Waverley Pharma's Current Ratio or its related term are showing as below:

TSXV:WAVE' s Current Ratio Range Over the Past 10 Years
Min: 0.2   Med: 1.19   Max: 7.43
Current: 0.2

During the past 8 years, Waverley Pharma's highest Current Ratio was 7.43. The lowest was 0.20. And the median was 1.19.

TSXV:WAVE's Current Ratio is ranked worse than
94.4% of 1553 companies
in the Biotechnology industry
Industry Median: 3.79 vs TSXV:WAVE: 0.20

Waverley Pharma Current Ratio Historical Data

The historical data trend for Waverley Pharma's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waverley Pharma Current Ratio Chart

Waverley Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 1.64 1.19 0.76 0.40 0.20

Waverley Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.31 0.22 0.17 0.20

Competitive Comparison of Waverley Pharma's Current Ratio

For the Biotechnology subindustry, Waverley Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Waverley Pharma's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Waverley Pharma's Current Ratio distribution charts can be found below:

* The bar in red indicates where Waverley Pharma's Current Ratio falls into.



Waverley Pharma Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Waverley Pharma's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=0.417/2.089
=0.20

Waverley Pharma's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=0.417/2.089
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Waverley Pharma  (TSXV:WAVE) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Waverley Pharma Current Ratio Related Terms

Thank you for viewing the detailed overview of Waverley Pharma's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Waverley Pharma (TSXV:WAVE) Business Description

Traded in Other Exchanges
Address
1250 Waverley Street, Suite 4, Winnipeg, MB, CAN, R3T 6C6
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.
Executives
Albert David Friesen 10% Security Holder, Director, Senior Officer

Waverley Pharma (TSXV:WAVE) Headlines

From GuruFocus